AlphaFold predicted structure
C2 · P06681

Mean pLDDT
88.3/ 100
Confident
752 residues
Confidence breakdown
- Very high(≥ 90)66%
- Confident(70–90)25%
- Low(50–70)4%
- Very low(< 50)5%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
complement C2
Annotations refreshed 11 hours ago.
Diagnostic Grade (Green)
COVID-19 research
BIALLELIC, autosomal or pseudoautosomalPrimary immunodeficiency or monogenic inflammatory bowel disease
BOTH monoallelic and biallelic, autosomal or pseudoautosomalEctodermal dysplasia
Familial cicatricial alopecia
Retinal disorders
MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknownImmunodeficiency due to a complement cascade protein anomaly
immunodeficiency due to a classical component pathway complement deficiency
systemic lupus erythematosus
complement deficiency
type 1 diabetes mellitus
age-related macular degeneration
macular degeneration
retinal disorder
lacrimal apparatus disorder
Eyelid malformation
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Complement C2
Precursor of the catalytic component of the C3 and C5 convertase complexes, which are part of the complement pathway, a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system (PubMed:12878586, PubMed:17027507, PubMed:18204047, PubMed:39914456, PubMed:39814882). Component C2 is part of the classical, lectin and GZMK complement systems (PubMed:12878586, PubMed:17027507, PubMed:18204047, PubMed:22691502, PubMed:39914456)
C2 · P06681

Mean pLDDT
88.3/ 100
Confident
752 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0